353 related articles for article (PubMed ID: 24080589)
1. The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
Boultwood J; Dolatshad H; Varanasi SS; Yip BH; Pellagatti A
Adv Biol Regul; 2014 Jan; 54():153-61. PubMed ID: 24080589
[TBL] [Abstract][Full Text] [Related]
2. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
[TBL] [Abstract][Full Text] [Related]
3. [Point mutations of genes encoding proteins involvedin RNA splicing in patients with myelodysplastic syndromes].
Barańska M; Czerwińska-Rybak J; Gil L; Komarnicki M
Pol Merkur Lekarski; 2015 Jan; 38(223):5-10. PubMed ID: 25763580
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
5. Spliceosomal factor mutations and mis-splicing in MDS.
Hershberger CE; Daniels NJ; Padgett RA
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
8. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
9. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
10. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
11. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
[TBL] [Abstract][Full Text] [Related]
12. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.
Visconte V; Makishima H; Maciejewski JP; Tiu RV
Leukemia; 2012 Dec; 26(12):2447-54. PubMed ID: 22678168
[TBL] [Abstract][Full Text] [Related]
13. Splicing factor mutations in myelodysplasia.
Ogawa S
Int J Hematol; 2012 Oct; 96(4):438-42. PubMed ID: 23054646
[TBL] [Abstract][Full Text] [Related]
14. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
15. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
16. Splicing factor mutant myelodysplastic syndromes: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2020 Jan; 75():100655. PubMed ID: 31558432
[TBL] [Abstract][Full Text] [Related]
17. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
[No Abstract] [Full Text] [Related]
18. Spliceosome and other novel mutations in chronic lymphocytic leukemia and myeloid malignancies.
Damm F; Nguyen-Khac F; Fontenay M; Bernard OA
Leukemia; 2012 Sep; 26(9):2027-31. PubMed ID: 22484420
[TBL] [Abstract][Full Text] [Related]
19. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment.
Pellagatti A; Boultwood J
Adv Biol Regul; 2023 Jan; 87():100920. PubMed ID: 36216757
[TBL] [Abstract][Full Text] [Related]
20. Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.
Madan V; Li J; Zhou S; Teoh WW; Han L; Meggendorfer M; Malcovati L; Cazzola M; Ogawa S; Haferlach T; Yang H; Koeffler HP
Am J Hematol; 2020 Feb; 95(2):133-143. PubMed ID: 31680297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
